Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 2912 entries
Sorted by: Best Match Show Resources per page
Hedgehog-targeted therapeutics uncouple the vicious cycle of bone metastasis.

Oncoimmunology

Hurchla MA, Weilbaecher KN.
PMID: 23243611
Oncoimmunology. 2012 Nov 01;1(8):1411-1413. doi: 10.4161/onci.21060.

Paracrine Hedgehog (Hh) signaling, in which tumor-derived Hh ligands activate stromal cells, has been implicated in the development and progression of many cancers. Recent data suggest that Hh-targeted therapeutics exert direct effects on host cells, thus interrupting a "vicious...

Cite
Hurchla MA, Weilbaecher KN. Hedgehog-targeted therapeutics uncouple the vicious cycle of bone metastasis. Oncoimmunology. 2012;1(8):1411-1413doi: 10.4161/onci.21060.
Hurchla, M. A., & Weilbaecher, K. N. (2012). Hedgehog-targeted therapeutics uncouple the vicious cycle of bone metastasis. Oncoimmunology, 1(8), 1411-1413. https://doi.org/10.4161/onci.21060
Hurchla, Michelle A, and Weilbaecher, Katherine N. "Hedgehog-targeted therapeutics uncouple the vicious cycle of bone metastasis." Oncoimmunology vol. 1,8 (2012): 1411-1413. doi: https://doi.org/10.4161/onci.21060
Hurchla MA, Weilbaecher KN. Hedgehog-targeted therapeutics uncouple the vicious cycle of bone metastasis. Oncoimmunology. 2012 Nov 01;1(8):1411-1413. doi: 10.4161/onci.21060. PMID: 23243611; PMCID: PMC3518520.
Copy Download .nbib Format: NLM
Parvoviruses-tools to fine-tune anticancer immune responses.

Oncoimmunology

Grekova SP, Rommelaere J, Raykov Z.
PMID: 23243613
Oncoimmunology. 2012 Nov 01;1(8):1417-1419. doi: 10.4161/onci.21097.

Oncolytic virotherapy represents a recent approach to anticancer therapy. Rodent autonomous parvoviruses (PVs) represent naturally oncolytic viruses that are non-pathogenic for humans but possess and extended tropism, being capable of infecting transformed cells of both rodent and human origin....

Cite
Grekova SP, Rommelaere J, Raykov Z. Parvoviruses-tools to fine-tune anticancer immune responses. Oncoimmunology. 2012;1(8):1417-1419doi: 10.4161/onci.21097.
Grekova, S. P., Rommelaere, J., & Raykov, Z. (2012). Parvoviruses-tools to fine-tune anticancer immune responses. Oncoimmunology, 1(8), 1417-1419. https://doi.org/10.4161/onci.21097
Grekova, Svitlana P, et al. "Parvoviruses-tools to fine-tune anticancer immune responses." Oncoimmunology vol. 1,8 (2012): 1417-1419. doi: https://doi.org/10.4161/onci.21097
Grekova SP, Rommelaere J, Raykov Z. Parvoviruses-tools to fine-tune anticancer immune responses. Oncoimmunology. 2012 Nov 01;1(8):1417-1419. doi: 10.4161/onci.21097. PMID: 23243613; PMCID: PMC3518522.
Copy Download .nbib Format: NLM
A new dynamic model of three cell interactions for CTL responses.

Oncoimmunology

Ahmed KA, Wang L, Xiang J.
PMID: 23243618
Oncoimmunology. 2012 Nov 01;1(8):1430-1432. doi: 10.4161/onci.21175.

The exact mechanisms of CD4 help in the generation of memory cytotoxic T lymphocytes (CTLs) remain largely illusive. We propose that dendritic cells (DCs) first interact with CD4(+) T cells, resulting in DC licensing and CD4(+) T-cell priming. Thereafter,...

Cite
Ahmed KA, Wang L, Xiang J. A new dynamic model of three cell interactions for CTL responses. Oncoimmunology. 2012;1(8):1430-1432doi: 10.4161/onci.21175.
Ahmed, K. A., Wang, L., & Xiang, J. (2012). A new dynamic model of three cell interactions for CTL responses. Oncoimmunology, 1(8), 1430-1432. https://doi.org/10.4161/onci.21175
Ahmed, Khawaja Ashfaque, et al. "A new dynamic model of three cell interactions for CTL responses." Oncoimmunology vol. 1,8 (2012): 1430-1432. doi: https://doi.org/10.4161/onci.21175
Ahmed KA, Wang L, Xiang J. A new dynamic model of three cell interactions for CTL responses. Oncoimmunology. 2012 Nov 01;1(8):1430-1432. doi: 10.4161/onci.21175. PMID: 23243618; PMCID: PMC3518527.
Copy Download .nbib Format: NLM
Umbilical cord blood CD34.

Oncoimmunology

Hoogstad-van Evert JS, Cany J, van den Brand D, Oudenampsen M, Brock R, Torensma R, Bekkers RL, Jansen JH, Massuger LF, Dolstra H.
PMID: 28919991
Oncoimmunology. 2017 May 11;6(8):e1320630. doi: 10.1080/2162402X.2017.1320630. eCollection 2017.

Adoptive transfer of allogeneic natural killer (NK) cells is an attractive therapy approach against ovarian carcinoma. Here, we evaluated the potency of highly active NK cells derived from human CD34+ haematopoietic stem and progenitor cells (HSPC) to infiltrate and...

Cite
Hoogstad-van Evert JS, Cany J, van den Brand D, et al. Umbilical cord blood CD34. Oncoimmunology. 2017;6(8):e1320630doi: 10.1080/2162402X.2017.1320630.
Hoogstad-van Evert, J. S., Cany, J., van den Brand, D., Oudenampsen, M., Brock, R., Torensma, R., Bekkers, R. L., Jansen, J. H., Massuger, L. F., & Dolstra, H. (2017). Umbilical cord blood CD34. Oncoimmunology, 6(8), e1320630. https://doi.org/10.1080/2162402X.2017.1320630
Hoogstad-van Evert, Janneke S, et al. "Umbilical cord blood CD34." Oncoimmunology vol. 6,8 (2017): e1320630. doi: https://doi.org/10.1080/2162402X.2017.1320630
Hoogstad-van Evert JS, Cany J, van den Brand D, Oudenampsen M, Brock R, Torensma R, Bekkers RL, Jansen JH, Massuger LF, Dolstra H. Umbilical cord blood CD34. Oncoimmunology. 2017 May 11;6(8):e1320630. doi: 10.1080/2162402X.2017.1320630. eCollection 2017. PMID: 28919991; PMCID: PMC5593716.
Copy Download .nbib Format: NLM
Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccination.

Oncoimmunology

Bol KF, Aarntzen EH, Hout FE, Schreibelt G, Creemers JH, Lesterhuis WJ, Gerritsen WR, Grunhagen DJ, Verhoef C, Punt CJ, Bonenkamp JJ, de Wilt JH, Figdor CG, de Vries IJ.
PMID: 26942068
Oncoimmunology. 2015 Jun 05;5(1):e1057673. doi: 10.1080/2162402X.2015.1057673. eCollection 2016.

Melanoma patients with regional metastatic disease are at high risk for recurrence and metastatic disease, despite radical lymph node dissection (RLND). We investigated the immunologic response and clinical outcome to adjuvant dendritic cell (DC) vaccination in melanoma patients with...

Cite
Bol KF, Aarntzen EH, Hout FE, et al. Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccination. Oncoimmunology. 2015;5(1):e1057673doi: 10.1080/2162402X.2015.1057673.
Bol, K. F., Aarntzen, E. H., Hout, F. E., Schreibelt, G., Creemers, J. H., Lesterhuis, W. J., Gerritsen, W. R., Grunhagen, D. J., Verhoef, C., Punt, C. J., Bonenkamp, J. J., de Wilt, J. H., Figdor, C. G., & de Vries, I. J. (2016). Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccination. Oncoimmunology, 5(1), e1057673. https://doi.org/10.1080/2162402X.2015.1057673
Bol, Kalijn F, et al. "Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccination." Oncoimmunology vol. 5,1 (2016): e1057673. doi: https://doi.org/10.1080/2162402X.2015.1057673
Bol KF, Aarntzen EH, Hout FE, Schreibelt G, Creemers JH, Lesterhuis WJ, Gerritsen WR, Grunhagen DJ, Verhoef C, Punt CJ, Bonenkamp JJ, de Wilt JH, Figdor CG, de Vries IJ. Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccination. Oncoimmunology. 2015 Jun 05;5(1):e1057673. doi: 10.1080/2162402X.2015.1057673. eCollection 2016. PMID: 26942068; PMCID: PMC4760342.
Copy Download .nbib Format: NLM
Hyperthermic intra-peritoneal chemotherapy and anticancer immune response.

Oncoimmunology

Zunino B, Ricci JE.
PMID: 26942072
Oncoimmunology. 2015 Jul 15;5(1):e1060392. doi: 10.1080/2162402X.2015.1060392. eCollection 2016.

Peritoneal carcinomatosis (PC) is a metastatic disease of primary tumors localized in the abdomen. Although this disease is considered a terminal condition, recent treatments combining surgery with heated intra-peritoneal chemotherapy (HIPEC) significantly increase patient survival. We have determined that...

Cite
Zunino B, Ricci JE. Hyperthermic intra-peritoneal chemotherapy and anticancer immune response. Oncoimmunology. 2015;5(1):e1060392doi: 10.1080/2162402X.2015.1060392.
Zunino, B., & Ricci, J. E. (2016). Hyperthermic intra-peritoneal chemotherapy and anticancer immune response. Oncoimmunology, 5(1), e1060392. https://doi.org/10.1080/2162402X.2015.1060392
Zunino, Barbara, and Ricci, Jean-Ehrland. "Hyperthermic intra-peritoneal chemotherapy and anticancer immune response." Oncoimmunology vol. 5,1 (2016): e1060392. doi: https://doi.org/10.1080/2162402X.2015.1060392
Zunino B, Ricci JE. Hyperthermic intra-peritoneal chemotherapy and anticancer immune response. Oncoimmunology. 2015 Jul 15;5(1):e1060392. doi: 10.1080/2162402X.2015.1060392. eCollection 2016. PMID: 26942072; PMCID: PMC4760280.
Copy Download .nbib Format: NLM
Enhancing natural killer cell-mediated lysis of lymphoma cells by combining therapeutic antibodies with CD20-specific immunoligands engaging NKG2D or NKp30.

Oncoimmunology

Kellner C, Günther A, Humpe A, Repp R, Klausz K, Derer S, Valerius T, Ritgen M, Brüggemann M, van de Winkel JG, Parren PW, Kneba M, Gramatzki M, Peipp M.
PMID: 26942070
Oncoimmunology. 2015 Jun 05;5(1):e1058459. doi: 10.1080/2162402X.2015.1058459. eCollection 2016.

Antibody-dependent cell-mediated cytotoxicity (ADCC) mediated through the IgG Fc receptor FcγRIIIa represents a major effector function of many therapeutic antibodies. In an attempt to further enhance natural killer (NK) cell-mediated ADCC, we combined therapeutic antibodies against CD20 and CD38...

Cite
Kellner C, Günther A, Humpe A, et al. Enhancing natural killer cell-mediated lysis of lymphoma cells by combining therapeutic antibodies with CD20-specific immunoligands engaging NKG2D or NKp30. Oncoimmunology. 2015;5(1):e1058459doi: 10.1080/2162402X.2015.1058459.
Kellner, C., Günther, A., Humpe, A., Repp, R., Klausz, K., Derer, S., Valerius, T., Ritgen, M., Brüggemann, M., van de Winkel, J. G., Parren, P. W., Kneba, M., Gramatzki, M., & Peipp, M. (2016). Enhancing natural killer cell-mediated lysis of lymphoma cells by combining therapeutic antibodies with CD20-specific immunoligands engaging NKG2D or NKp30. Oncoimmunology, 5(1), e1058459. https://doi.org/10.1080/2162402X.2015.1058459
Kellner, Christian, et al. "Enhancing natural killer cell-mediated lysis of lymphoma cells by combining therapeutic antibodies with CD20-specific immunoligands engaging NKG2D or NKp30." Oncoimmunology vol. 5,1 (2016): e1058459. doi: https://doi.org/10.1080/2162402X.2015.1058459
Kellner C, Günther A, Humpe A, Repp R, Klausz K, Derer S, Valerius T, Ritgen M, Brüggemann M, van de Winkel JG, Parren PW, Kneba M, Gramatzki M, Peipp M. Enhancing natural killer cell-mediated lysis of lymphoma cells by combining therapeutic antibodies with CD20-specific immunoligands engaging NKG2D or NKp30. Oncoimmunology. 2015 Jun 05;5(1):e1058459. doi: 10.1080/2162402X.2015.1058459. eCollection 2016. PMID: 26942070; PMCID: PMC4760288.
Copy Download .nbib Format: NLM
CD11b+Ly6G+ cells inhibit tumor growth by suppressing IL-17 production at early stages of tumorigenesis.

Oncoimmunology

Liu Y, O'Leary CE, Wang LS, Bhatti TR, Dai N, Kapoor V, Liu P, Mei J, Guo L, Oliver PM, Albelda SM, Worthen GS.
PMID: 26942073
Oncoimmunology. 2015 Jul 28;5(1):e1061175. doi: 10.1080/2162402X.2015.1061175. eCollection 2016.

Neutrophils are important innate immune cells involved in microbial clearance at the sites of infection. However, their role in cancer development is unclear. We hypothesized that neutrophils mediate antitumor effects in early tumorigenesis. To test this, we first studied...

Cite
Liu Y, O'Leary CE, Wang LS, et al. CD11b+Ly6G+ cells inhibit tumor growth by suppressing IL-17 production at early stages of tumorigenesis. Oncoimmunology. 2015;5(1):e1061175doi: 10.1080/2162402X.2015.1061175.
Liu, Y., O'Leary, C. E., Wang, L. S., Bhatti, T. R., Dai, N., Kapoor, V., Liu, P., Mei, J., Guo, L., Oliver, P. M., Albelda, S. M., & Worthen, G. S. (2016). CD11b+Ly6G+ cells inhibit tumor growth by suppressing IL-17 production at early stages of tumorigenesis. Oncoimmunology, 5(1), e1061175. https://doi.org/10.1080/2162402X.2015.1061175
Liu, Yuhong, et al. "CD11b+Ly6G+ cells inhibit tumor growth by suppressing IL-17 production at early stages of tumorigenesis." Oncoimmunology vol. 5,1 (2016): e1061175. doi: https://doi.org/10.1080/2162402X.2015.1061175
Liu Y, O'Leary CE, Wang LS, Bhatti TR, Dai N, Kapoor V, Liu P, Mei J, Guo L, Oliver PM, Albelda SM, Worthen GS. CD11b+Ly6G+ cells inhibit tumor growth by suppressing IL-17 production at early stages of tumorigenesis. Oncoimmunology. 2015 Jul 28;5(1):e1061175. doi: 10.1080/2162402X.2015.1061175. eCollection 2016. PMID: 26942073; PMCID: PMC4760327.
Copy Download .nbib Format: NLM
Doubling the blockade for melanoma immunotherapy.

Oncoimmunology

Galluzzi L, Eggermont A, Kroemer G.
PMID: 26942094
Oncoimmunology. 2015 Oct 29;5(1):e1106127. doi: 10.1080/2162402X.2015.1106127. eCollection 2016.

No abstract available.

Cite
Galluzzi L, Eggermont A, Kroemer G. Doubling the blockade for melanoma immunotherapy. Oncoimmunology. 2015;5(1):e1106127doi: 10.1080/2162402X.2015.1106127.
Galluzzi, L., Eggermont, A., & Kroemer, G. (2016). Doubling the blockade for melanoma immunotherapy. Oncoimmunology, 5(1), e1106127. https://doi.org/10.1080/2162402X.2015.1106127
Galluzzi, Lorenzo, et al. "Doubling the blockade for melanoma immunotherapy." Oncoimmunology vol. 5,1 (2016): e1106127. doi: https://doi.org/10.1080/2162402X.2015.1106127
Galluzzi L, Eggermont A, Kroemer G. Doubling the blockade for melanoma immunotherapy. Oncoimmunology. 2015 Oct 29;5(1):e1106127. doi: 10.1080/2162402X.2015.1106127. eCollection 2016. PMID: 26942094; PMCID: PMC4760293.
Copy Download .nbib Format: NLM
Mammaglobin-A is a target for breast cancer vaccination.

Oncoimmunology

Kim SW, Goedegebuure P, Gillanders WE.
PMID: 27057470
Oncoimmunology. 2016 Feb 26;5(2):e1069940. doi: 10.1080/2162402X.2015.1069940. eCollection 2016 Feb.

We recently completed a phase 1 clinical trial demonstrating the safety of a mammaglobin-A DNA vaccine in patients with metastatic breast cancer. We are currently enrolling patients with early stage breast cancer in a phase 1b clinical trial. The...

Cite
Kim SW, Goedegebuure P, Gillanders WE. Mammaglobin-A is a target for breast cancer vaccination. Oncoimmunology. 2016;5(2):e1069940doi: 10.1080/2162402X.2015.1069940.
Kim, S. W., Goedegebuure, P., & Gillanders, W. E. (2016). Mammaglobin-A is a target for breast cancer vaccination. Oncoimmunology, 5(2), e1069940. https://doi.org/10.1080/2162402X.2015.1069940
Kim, Samuel W, et al. "Mammaglobin-A is a target for breast cancer vaccination." Oncoimmunology vol. 5,2 (2016): e1069940. doi: https://doi.org/10.1080/2162402X.2015.1069940
Kim SW, Goedegebuure P, Gillanders WE. Mammaglobin-A is a target for breast cancer vaccination. Oncoimmunology. 2016 Feb 26;5(2):e1069940. doi: 10.1080/2162402X.2015.1069940. eCollection 2016 Feb. PMID: 27057470; PMCID: PMC4801441.
Copy Download .nbib Format: NLM
T cells targeting NY-ESO-1 demonstrate efficacy against disseminated neuroblastoma.

Oncoimmunology

Singh N, Kulikovskaya I, Barrett DM, Binder-Scholl G, Jakobsen B, Martinez D, Pawel B, June CH, Kalos MD, Grupp SA.
PMID: 26942053
Oncoimmunology. 2015 Aug 12;5(1):e1040216. doi: 10.1080/2162402X.2015.1040216. eCollection 2016.

The cancer-testis antigen NY-ESO-1 is expressed by many solid tumors and has limited expression by mature somatic tissues, making it a highly attractive target for tumor immunotherapy. Targeting NY-ESO-1 using engineered T cells has demonstrated clinical efficacy in the...

Cite
Singh N, Kulikovskaya I, Barrett DM, et al. T cells targeting NY-ESO-1 demonstrate efficacy against disseminated neuroblastoma. Oncoimmunology. 2015;5(1):e1040216doi: 10.1080/2162402X.2015.1040216.
Singh, N., Kulikovskaya, I., Barrett, D. M., Binder-Scholl, G., Jakobsen, B., Martinez, D., Pawel, B., June, C. H., Kalos, M. D., & Grupp, S. A. (2016). T cells targeting NY-ESO-1 demonstrate efficacy against disseminated neuroblastoma. Oncoimmunology, 5(1), e1040216. https://doi.org/10.1080/2162402X.2015.1040216
Singh, Nathan, et al. "T cells targeting NY-ESO-1 demonstrate efficacy against disseminated neuroblastoma." Oncoimmunology vol. 5,1 (2016): e1040216. doi: https://doi.org/10.1080/2162402X.2015.1040216
Singh N, Kulikovskaya I, Barrett DM, Binder-Scholl G, Jakobsen B, Martinez D, Pawel B, June CH, Kalos MD, Grupp SA. T cells targeting NY-ESO-1 demonstrate efficacy against disseminated neuroblastoma. Oncoimmunology. 2015 Aug 12;5(1):e1040216. doi: 10.1080/2162402X.2015.1040216. eCollection 2016. PMID: 26942053; PMCID: PMC4760344.
Copy Download .nbib Format: NLM
Identification of glypican-3-derived long peptides activating both CD8.

Oncoimmunology

Sayem MA, Tomita Y, Yuno A, Hirayama M, Irie A, Tsukamoto H, Senju S, Yuba E, Yoshikawa T, Kono K, Nakatsura T, Nishimura Y.
PMID: 26942076
Oncoimmunology. 2015 Aug 31;5(1):e1062209. doi: 10.1080/2162402X.2015.1062209. eCollection 2016.

In a recent phase I clinical trial, a vaccine consisting of glypican-3 (GPC3)-derived CTL epitopes was found to be safe and induced measurable immune and clinical responses in patients with hepatocellular carcinoma (HCC). The aim of this study was...

Cite
Sayem MA, Tomita Y, Yuno A, et al. Identification of glypican-3-derived long peptides activating both CD8. Oncoimmunology. 2015;5(1):e1062209doi: 10.1080/2162402X.2015.1062209.
Sayem, M. A., Tomita, Y., Yuno, A., Hirayama, M., Irie, A., Tsukamoto, H., Senju, S., Yuba, E., Yoshikawa, T., Kono, K., Nakatsura, T., & Nishimura, Y. (2016). Identification of glypican-3-derived long peptides activating both CD8. Oncoimmunology, 5(1), e1062209. https://doi.org/10.1080/2162402X.2015.1062209
Sayem, Mohammad A, et al. "Identification of glypican-3-derived long peptides activating both CD8." Oncoimmunology vol. 5,1 (2016): e1062209. doi: https://doi.org/10.1080/2162402X.2015.1062209
Sayem MA, Tomita Y, Yuno A, Hirayama M, Irie A, Tsukamoto H, Senju S, Yuba E, Yoshikawa T, Kono K, Nakatsura T, Nishimura Y. Identification of glypican-3-derived long peptides activating both CD8. Oncoimmunology. 2015 Aug 31;5(1):e1062209. doi: 10.1080/2162402X.2015.1062209. eCollection 2016. PMID: 26942076; PMCID: PMC4760284.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 2912 entries